Subdomain IB is the third major drug binding region of human serum albumin: Toward the three-sites model

Molecular Pharmaceutics

Volumn 10, Issue 5, 2013, Pages 1668-1682

  Zsila, Ferenc ^a  

^a INSTITUTE OF MATERIALS AND ENVIRONMENTAL CHEMISTRY   (Hungary)

Author keywords

albumin; allosteric interaction; anticancer drugs; biliverdin; circular dichroism; drug displacement; hemin; ligand binding; subdomain IB; Sudlow's site

Indexed keywords

ARISTOLOCHIC ACID; AZOCARMINE B; BILE ACID; BILIVERDIN; CAMPTOTHECIN; CARBENOXOLONE; DAUNORUBICIN; DICOUMAROL; DOXORUBICIN; DYE; GLYCYRRHETINIC ACID; HEMIN; HUMAN SERUM ALBUMIN; METHYL ORANGE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE KINASE INHIBITOR; SURAMIN; TENIPOSIDE; UNCLASSIFIED DRUG; DRUG; FATTY ACID; LIGAND; SERUM ALBUMIN;

ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; DRUG BINDING SITE; DRUG PROTEIN BINDING; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DOMAIN; BINDING COMPETITION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE; SPECTROPHOTOMETRY;

ALLOSTERIC SITE; BILIVERDINE; BINDING SITES; BINDING, COMPETITIVE; CIRCULAR DICHROISM; FATTY ACIDS; HEMIN; HUMANS; LIGANDS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PROTEIN STRUCTURE, TERTIARY; SERUM ALBUMIN; SPECTROPHOTOMETRY;

EID: 84877265704     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400027q     Document Type: Article

References (82)

1. Kratochwil, N. A.; Huber, W.; Muller, F.; Kansy, M.; Gerber, P. R. Predicting plasma protein binding of drugs: a new approach Biochem. Pharmacol. 2002, 64, 1355-1374
2. Curry, S. Lessons from the crystallographic analysis of small molecule binding to human serum albumin Drug Metab. Pharmacokinet. 2009, 24, 342-357
3. Carter, D. C.; Ho, J. X. Structure of serum albumin Adv. Protein Chem. 1994, 45, 153-203
4. Ghuman, J.; Zunszain, P. A.; Petitpas, I.; Bhattacharya, A. A.; Otagiri, M.; Curry, S. Structural basis of the drug-binding specificity of human serum albumin J. Mol. Biol. 2005, 353, 38-52
5. Buttar, D.; Colclough, N.; Gerhardt, S.; MacFaul, P. A.; Phillips, S. D.; Plowright, A.; Whittamore, P.; Tam, K.; Maskos, K.; Steinbacher, S.; Steuber, H. A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions Bioorg. Med. Chem. 2010, 18, 7486-7496
6. Yang, F.; Bian, C.; Zhu, L.; Zhao, G.; Huang, Z.; Huang, M. Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin J. Struct. Biol. 2007, 157, 348-355
7. Petitpas, I.; Bhattacharya, A. A.; Twine, S.; East, M.; Curry, S. Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I J. Biol. Chem. 2001, 276, 22804-22809
8. Ryan, A. J.; Ghuman, J.; Zunszain, P. A.; Chung, C. W.; Curry, S. Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin J. Struct. Biol. 2011, 174, 84-91
9. Zunszain, P. A.; Ghuman, J.; McDonagh, A. F.; Curry, S. Crystallographic analysis of human serum albumin complexed with 4 Z,15 E -bilirubin-IXα J. Mol. Biol. 2008, 381, 394-406
10. Zunszain, P. A.; Ghuman, J.; Komatsu, T.; Tsuchida, E.; Curry, S. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid BMC Struct. Biol. 2003, 3, 6
11. Wardell, M.; Wang, Z.; Ho, J. X.; Robert, J.; Ruker, F.; Ruble, J.; Carter, D. C. The atomic structure of human methemalbumin at 1.9 Å Biochem. Biophys. Res. Commun. 2002, 291, 813-819
12. Bhattacharya, A. A.; Grune, T.; Curry, S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin J. Mol. Biol. 2000, 303, 721-732
13. Ryan, A. J.; Chung, C. W.; Curry, S. Crystallographic analysis reveals the structural basis of the high-affinity binding of iophenoxic acid to human serum albumin BMC Struct. Biol. 2011, 11, 18
14. Lejon, S.; Cramer, J. F.; Nordberg, P. Structural basis for the binding of naproxen to human serum albumin in the presence of fatty acids and the GA module Acta Crystallogr., Sect. F 2008, 64, 64-69
15. Zhu, L.; Yang, F.; Chen, L.; Meehan, E. J.; Huang, M. A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography J. Struct. Biol. 2008, 162, 40-49
16. Curry, S.; Mandelkow, H.; Brick, P.; Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites Nat. Struct. Biol. 1998, 5, 827-835
17. Carter, D. C. Crystallographic survey of albumin drug interaction and preliminary applications in cancer chemotherapy. In Burger's Medicinal Chemistry and Drug Discovery, 7 th ed.; Abraham, D. J.; Rotella, D. P., Eds.; John Wiley & Sons, Inc.: New York, 2010; pp 437-467.
18. Carter, D. C.; Ho, J.; Wang, Z. Atomic coordinates of albumin drug complexes and method of use of pharmaceutical development. United States Patent Application 20070219767, 2007.
19. Burke, T. G.; Carter, D. C. Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds. United States Patent 7691872, 2010.
20. Carter, D. C.; Ho, J.; Wang, Z. Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties. United States Patent Application 20070043509, 2007.
21. Wang, Z.; Ho, J.; Carter, D. C. Methods and compositions for increasing the safety and efficacy of albumin-binding drugs. United States Patent Application 20060234960, 2006.
22. Carter, D. C. Coumarin analog compounds for safer anticoagulant treatment. United States Patent 7439077, 2008.
23. Kragh-Hansen, U. Molecular aspects of ligand binding to serum albumin Pharmacol. Rev. 1981, 33, 17-53
24. Kragh-Hansen, U. Relations between high-affinity binding sites of markers for binding regions on human serum albumin Biochem. J. 1985, 225, 629-638
25. Zsila, F.; Bikádi, Z.; Simonyi, M. Probing the binding of the flavonoid, quercetin to human serum albumin by circular dichroism, electronic absorption spectroscopy and molecular modelling methods Biochem. Pharmacol. 2003, 65, 447-456
26. Trull, F. R.; Ibars, O.; Lightner, D. A. Conformation inversion of bilirubin formed by reduction of the biliverdin-human serum albumin complex: evidence from circular dichroism Arch. Biochem. Biophys. 1992, 298, 710-714
27. Blauer, G.; Wagniere, G. Conformation of bilirubin and biliverdin in their complexes with serum albumin J. Am. Chem. Soc. 1975, 97, 1949-1954
28. Boiadjiev, S. E.; Lightner, D. A. Optical activity and stereochemistry of linear oligopyrroles and bile pigments Tetrahedron: Asymmetry 1999, 10, 607-655
29. Carter, D. C.; Ho, J.; Wang, Z. Atomic structure of the hemalbumin complex and its use in designing therapeutic compounds. United States Patent 7208580, 2007.
30. Bertucci, C. Enantioselective inhibition of the binding of rac -profens to human serum albumin induced by lithocholate Chirality 2001, 13, 372-378
31. Bertucci, C.; Cimitan, S. Inhibition of drug binding to human serum albumin by cholecystographic agents Farmaco 2003, 58, 901-908
32. Ahlfors, C. E. Competitive interaction of biliverdin and bilirubin only at the primary bilirubin binding site on human albumin Anal. Biochem. 1981, 110, 295-307
33. Minchiotti, L.; Galliano, M.; Zapponi, M. C.; Tenni, R. The structural characterization and bilirubin-binding properties of albumin Herborn, a [Lys240 - >Glu] albumin mutant Eur. J. Biochem. 1993, 214, 437-444
34. Fehske, K. J.; Schlafer, U.; Wollert, U.; Muller, W. E. Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone Mol. Pharmacol. 1982, 21, 387-393
35. Roda, A.; Cappelleri, G.; Aldini, R.; Roda, E.; Barbara, L. Quantitative aspects of the interaction of bile acids with human serum albumin J. Lipid Res. 1982, 23, 490-495
36. 1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors Curr. Med. Chem. 2009, 16, 1964-1977
37. Ambrosetti, R.; Bianchini, R.; Fisichella, S.; Fichera, M.; Zandomeneghi, M. Resolution of the absorbance and CD spectra and formation constants of the complexes between human serum albumin and methyl orange Chem.-Eur. J. 1996, 2, 149-156
38. Zsila, F. Aromatic side-chain cluster of biotin binding site of avidin allows circular dichroism spectroscopic investigation of its ligand binding properties J. Mol. Recognit. 2011, 24, 995-1006
39. Hein, K. L.; Kragh-Hansen, U.; Morth, J. P.; Jeppesen, M. D.; Otzen, D.; Moller, J. V.; Nissen, P. Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin J. Struct. Biol. 2010, 171, 353-360
40. Fanali, G.; di Masi, A.; Trezza, V.; Marino, M.; Fasano, M.; Ascenzi, P. Human serum albumin: From bench to bedside Mol. Aspects Med. 2012, 33, 209-290
41. Sakai, T.; Takadate, A.; Otagiri, M. Characterization of binding site of uremic toxins on human serum albumin Biol. Pharm. Bull. 1995, 18, 1755-1761
42. Ascenzi, P.; Bocedi, A.; Bolli, A.; Fasano, M.; Notari, S.; Polticelli, F. Allosteric modulation of monomeric proteins Biochem. Mol. Biol. Educ. 2005, 33, 169-176
43. Blauer, G. Optical activity of conjugated proteins Struct. Bonding (Berlin) 1974, 18, 69-129
44. Blauer, G.; Sreerama, N.; Woody, R. W. Optical activity of hemoproteins in the Soret region. Circular dichroism of the heme undecapeptide of cytochrome c in aqueous solution Biochemistry 1993, 32, 6674-6679
45. Kiefl, C.; Sreerama, N.; Haddad, R.; Sun, L.; Jentzen, W.; Lu, Y.; Qiu, Y.; Shelnutt, J. A.; Woody, R. W. Heme distortions in sperm-whale carbonmonoxy myoglobin: correlations between rotational strengths and heme distortions in MD-generated structures J. Am. Chem. Soc. 2002, 124, 3385-3394
46. Pasternack, R. F.; Gibbs, E. J.; Hoeflin, E.; Kosar, W. P.; Kubera, G.; Skowronek, C. A.; Wong, N. M.; Muller-Eberhard, U. Hemin binding to serum proteins and the catalysis of interprotein transfer Biochemistry 1983, 22, 1753-1758
47. Adams, P. A.; Berman, M. C. Kinetics and mechanism of the interaction between human serum albumin and monomeric haemin Biochem. J. 1980, 191, 95-102
48. Fleury, F.; Kudelina, I.; Nabiev, I. Interactions of lactone, carboxylate and self-aggregated forms of camptothecin with human and bovine serum albumins FEBS Lett. 1997, 406, 151-156
49. Fleury, F.; Ianoul, A.; Berjot, M.; Feofanov, A.; Alix, A. J.; Nabiev, I. Camptothecin-binding site in human serum albumin and protein transformations induced by drug binding FEBS Lett. 1997, 411, 215-220
50. Burke, T. G.; Mi, Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability J. Med. Chem. 1994, 37, 40-46
51. Mi, Z.; Burke, T. G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components Biochemistry 1994, 33, 10325-10336
52. Mi, Z.; Burke, T. G. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study Biochemistry 1994, 33, 12540-12545
53. Chignell, C. F. Drug-protein binding: recent advances in methodology: spectroscopic techniques Ann. N.Y. Acad. Sci. 1973, 226, 44-59
54. Mi, Z.; Malak, H.; Burke, T. G. Reduced albumin binding promotes the stability and activity of topotecan in human blood Biochemistry 1995, 34, 13722-13728
55. Allen, L. M.; Creaven, P. J. Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives Eur. J. Cancer. 1975, 11, 697-707
56. Chassany, O.; Urien, S.; Claudepierre, P.; Bastian, G.; Tillement, J. P. Comparative serum protein binding of anthracycline derivatives Cancer Chemother. Pharmacol. 1996, 38, 571-573
57. Demant, E. J.; Friche, E. Equilibrium binding of anthracycline cytostatics to serum albumin and small unilamellar phospholipid vesicles as measured by gel filtration Biochem. Pharmacol. 1998, 55, 27-32
58. Trynda-Lemiesz, L.; Kozlowski, H. Some aspect of the interactions of adriamycin with human serum albumin Bioorg. Med. Chem. 1996, 4, 1709-1713
59. Tang, K.; Qin, Y. M.; Lin, A. H.; Hu, X.; Zou, G. L. Interaction of daunomycin antibiotic with human serum albumin: investigation by resonant mirror biosensor technique, fluorescence spectroscopy and molecular modeling methods J. Pharm. Biomed. Anal. 2005, 39, 404-410
60. Vahedian-Movahed, H.; Saberi, M. R.; Chamani, J. Comparison of binding interactions of lomefloxacin to serum albumin and serum transferrin by resonance light scattering and fluorescence quenching methods J. Biomol. Struct. Dyn. 2011, 28, 483-502
61. Subramanyam, R.; Goud, M.; Sudhamalla, B.; Reddeem, E.; Gollapudi, A.; Nellaepalli, S.; Yadavalli, V.; Chinnaboina, M.; Amooru, D. G. Novel binding studies of human serum albumin with trans -feruloyl maslinic acid J. Photochem. Photobiol., B 2009, 95, 81-88
62. Bos, O. J.; Vansterkenburg, E. L.; Boon, J. P.; Fischer, M. J.; Wilting, J.; Janssen, L. H. Location and characterization of the suramin binding sites of human serum albumin Biochem. Pharmacol. 1990, 40, 1595-1599
63. Simard, J. R.; Zunszain, P. A.; Hamilton, J. A.; Curry, S. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis J. Mol. Biol. 2006, 361, 336-351
64. Huthwohl, B.; Jahnchen, E. Displacement of phenprocoumon (Marcumar) from albumin by sulfonylurea compounds, suramin, and ioglycamic acid Naunyn-Schmiedeberg's Arch. Pharmacol. 1972, 273, 204-212
65. Sudlow, G.; Birkett, D. J.; Wade, D. N. Further characterization of specific drug binding sites on human serum albumin Mol. Pharmacol. 1976, 12, 1052-1061
66. Otagiri, M.; Fleitman, J. S.; Perrin, J. H. Investigations into the binding of phenprocoumon to albumin using fluorescence spectroscopy J. Pharm. Pharmacol. 1980, 32, 478-482
67. Kroll, F.; Karlsson, J. A.; Lundberg, J. M.; Persson, C. G. Albumin protects against capsaicin- and adenosine-induced bronchoconstriction and reduces overflow of calcitonin gene-related peptide from guinea-pig lung Acta Physiol. Scand. 1990, 139, 223-232
68. Yagi, T. Inhibition by capsaicin of NADH-quinone oxidoreductases is correlated with the presence of energy-coupling site 1 in various organisms Arch. Biochem. Biophys. 1990, 281, 305-311
69. Szallasi, A.; Lewin, N. E.; Blumberg, P. M. Identification of α-1-acid glycoprotein (orosomucoid) as a major vanilloid binding protein in serum J. Pharmacol. Exp. Ther. 1992, 262, 883-888
70. Karnaukhova, E. Interactions of human serum albumin with retinoic acid, retinal and retinyl acetate Biochem. Pharmacol. 2007, 73, 901-910
71. Zsila, F.; Bikádi, Z.; Simonyi, M. Induced chirality upon crocetin binding to human serum albumin: origin and nature Tetrahedron: Asymmetry 2001, 12, 3125-3137
72. Sklar, L. A.; Hudson, B. S.; Simoni, R. D. Conjugated polyene fatty acids as fluorescent probes: binding to bovine serum albumin Biochemistry 1977, 16, 5100-5108
73. 1-acid glycoprotein Biochem. Pharmacol. 1991, 41, 377-383
74. Bertucci, C.; Andrisano, V.; Gotti, R.; Cavrini, V. Modulation of chromatographic performances of HSA-based HPLC column by reversible binding of lithocholic acid Chromatographia 2001, 53, 515-518
75. Brodersen, R. Fusidic acid binding to serum albumin and interaction with binding of bilirubin Acta Paediatr. Scand. 1985, 74, 874-880
76. Güttler, F.; Tybring, L.; Engberg-Pedersen, H. Interaction of albumin and fusidic acid Br. J. Pharmacol. 1971, 43, 151-160
77. Rieutord, A.; Bourget, P.; Troché, G.; Zazzo, J. F. In vitro study of the protein binding of fusidic acid: a contribution to the comprehension of its pharmacokinetic behavior Int. J. Pharm. 1995, 119, 57-64
78. Parke, D. V.; Lindup, W. E. Quantitative and qualitative aspects of the plasma protein binding of carbenoxolone, an ulcer-healing drug Ann. N.Y. Acad. Sci. 1973, 226, 200-213
79. Ishida, S.; Ichikawa, T.; Sakiya, Y. Binding of glycyrrhetinic acid to rat plasma, rat serum albumin, human serum, and human serum albumin Chem. Pharm. Bull. (Tokyo) 1988, 36, 440-443
80. Tang, J.; Luan, F.; Chen, X. Binding analysis of glycyrrhetinic acid to human serum albumin: fluorescence spectroscopy, FTIR, and molecular modeling Bioorg. Med. Chem. 2006, 14, 3210-3217
81. Gottfried, S.; Parke, D. V.; Sacra, P. J.; Thornton, P. C. Studies of the interaction of carbenoxolone sodium and warfarin sodiun in vivo Br. J. Pharmacol. 1977, 60, 280P-281P
82. Colussi, D. M.; Parisot, C.; Rossolino, M. L.; Brunner, L. A.; Lefevre, G. Y. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist J. Clin. Pharmacol. 1997, 37, 214-221